Business Context and Reporting Period
Company: TherapeuticsMD, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 6, 2019
Event: Entry into a Material Definitive Agreement (Licensing and Supply Agreement).
Key Financial Metrics and Transaction Terms
This filing details a licensing agreement rather than periodic financial results. Key financial terms of the agreement include:
- Upfront Payment: EUR 14 million in cash payable within 60 days.
- Regulatory Milestones: Up to EUR 2 million contingent on regulatory approvals in specified markets.
- Sales Milestones: Up to EUR 27.5 million contingent on aggregate annual net sales ranging from EUR 25 million to EUR 100 million.
- Royalties: Quarterly payments based on net sales of BIJUVA and IMVEXXY in the Territory.
- Total Potential Cash Consideration: Up to EUR 43.5 million (excluding royalties).
Note: The filing text does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures for the Company.
Material Changes and Agreement Scope
The Company granted Theramex HQ UK Limited an exclusive, perpetual license to commercialize FDA-approved products BIJUVA (estradiol and progesterone capsules) and IMVEXXY (estradiol vaginal inserts) outside the United States, excluding Canada and Israel.
- Territory: Global excluding the U.S., Canada, and Israel.
- Responsibilities: Theramex is responsible for all regulatory and commercial activities in the Territory.
- Supply: TherapeuticsMD agreed to supply the products to Theramex.
- Termination: The Company may terminate if Theramex fails to submit required regulatory applications within specified timeframes or challenges the Company's patents.
Outlook, Risks, and Management Commentary
Management Commentary: The Company and Theramex will form a joint product committee to oversee activities under the agreement. A press release was issued on June 7, 2019, to announce the deal.
Risks and Contingencies:
- Regulatory Risk: Milestone payments depend on Theramex securing regulatory approvals in specified markets.
- Commercial Risk: Sales milestones depend on Theramex achieving specific net sales thresholds.
- Termination Risk: The agreement is subject to termination for material breach, bankruptcy, or failure to meet regulatory submission deadlines.
Investor Verification Checklist
- Verify the conversion rate of EUR to USD for the EUR 14 million upfront payment and potential milestones.
- Confirm the specific "specified markets" and "specified time periods" for regulatory submissions in the full Licensing Agreement.
- Review the royalty percentage rates, which are not explicitly stated in this summary.
- Check the Company's cash position to assess the impact of the upfront payment on liquidity.
- Examine the full text of the Licensing Agreement (to be filed as an exhibit to the Q2 2019 Form 10-Q) for detailed termination clauses and sublicensing restrictions.